Phase 1 Study to Evaluate the Safety of Reducing the Prophylactic Dose of Dexamethasone around Docetaxel Infusion in Patients with Prostate and Breast Cancer

SIMPLE SUMMARY: Docetaxel has been approved as an anti-cancer agent in 1995. High rates of hypersensitivity reactions (HSR) and fluid retention were observed when this agent was first introduced. The use of high dose systemic corticosteroids around docetaxel infusion appeared to decrease the inciden...

Descripción completa

Detalles Bibliográficos
Autores principales: Lugtenberg, Rieneke T., de Groot, Stefanie, Houtsma, Danny, Dezentjé, Vincent O., Vulink, Annelie J. E., Fischer, Maarten J., Portielje, Johanneke E. A., van der Hoeven, Jacobus J. M., Gelderblom, Hans, Pijl, Hanno, Kroep, Judith R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046524/
https://www.ncbi.nlm.nih.gov/pubmed/36980577
http://dx.doi.org/10.3390/cancers15061691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046524/
https://www.ncbi.nlm.nih.gov/pubmed/36980577
http://dx.doi.org/10.3390/cancers15061691

Ejemplares similares